3-溴-2,6-二甲氧基苯甲酸 | 73219-89-3

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-溴-2,6-二甲氧基苯甲酸
• 英文名称: 3-bromo-2,6-dimethoxybenzoic acid
• CAS: 73219-89-3
• 化学式: C₉H₉BrO₄
• 分子量: 261.072
• InChiKey: CUQANLQRQJHIQE-UHFFFAOYSA-N

物化性质

• 熔点：
  146 °C
• 沸点：
  359.8±42.0 °C(Predicted)
• 密度：
  1.571±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、DMSO（少许）、乙酸乙酯（少许）
• 稳定性/保质期：
  远离氧化物。

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 安全说明：
  S26,S37
• 危险类别码：
  R36/37/38
• 海关编码：
  2918990090
• 危险性防范说明：
  P261,P264,P271,P280,P302+P352,P304+P340,P305+P351+P338,P312,P362,P403+P233,P501
• 危险性描述：
  H315,H319,H335
• 储存条件：
  请将存放在密封容器内，并储存在阴凉、干燥处。务必远离氧化剂。

SDS

Name:	3-Bromo-2 6-dimethoxybenzoic acid Material Safety Data Sheet
Synonym:	None know
CAS:	73219-89-3

Section 1 - Chemical Product MSDS Name:3-Bromo-2 6-dimethoxybenzoic acid Material Safety Data Sheet
Synonym:None know

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
73219-89-3	3-Bromo-2,6-dimethoxybenzoic acid	97+%	unlisted

Hazard Symbols: XN
Risk Phrases: 22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful if swallowed. Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Causes respiratory tract irritation.
Chronic:
No information found.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Avoid generating dusty conditions.

---

Section 7 - HANDLING and STORAGE
Handling:
Use with adequate ventilation. Minimize dust generation and accumulation. Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 73219-89-3: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: White
Odor: Mild/faint
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 146 - 148 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H9BrO4
Molecular Weight: 261.07

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable under normal temperatures and pressures.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, strong bases, amines.
Hazardous Decomposition Products:
Carbon monoxide, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 73219-89-3 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
3-Bromo-2,6-dimethoxybenzoic acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
IMO
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing Group:
RID/ADR
Shipping Name: Not regulated.
Hazard Class:
UN Number:
Packing group:

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 22 Harmful if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 22 Do not breathe dust.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 73219-89-3: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 73219-89-3 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 73219-89-3 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

上下游信息

• 上游原料

  中文名称	英文名称	CAS号	化学式	分子量
  3-溴-2,6-二甲氧基苯甲酸甲酯	3-Brom-2,6-dimethoxy-benzoesaeure-methylester	65977-12-0	C10H11BrO4	275.099
  2,6-二甲氧基苯甲酸	2-6-dimethoxybenzoic acid	1466-76-8	C9H10O4	182.176

• 下游产品

  中文名称	英文名称	CAS号	化学式	分子量
  3-溴-2,6-二甲氧基苯甲酸甲酯	3-Brom-2,6-dimethoxy-benzoesaeure-methylester	65977-12-0	C10H11BrO4	275.099
  ——	3-bromo-2,6-dimethoxybenzyl alcohol	586392-15-6	C9H11BrO3	247.089
  ——	3-bromo-2,6-dimethoxybenzyl methyl ether	586392-17-8	C10H13BrO3	261.115
  3-溴-5-氯-2,6-二甲氧基苯甲酸	3-bromo-5-chloro-2,6-dimethoxybenzoic acid	73219-92-8	C9H8BrClO4	295.517
  3-溴-2,6-二甲氧基苯甲酰氯	3-bromo-2,6-dimethoxybenzoyl chloride	84225-91-2	C9H8BrClO3	279.518
  ——	1-acetyl-3-bromo-2,6-dimethoxybenzene	1259663-52-9	C10H11BrO3	259.1
  ——	1-(3-bromo-2,6-dimethoxyphenyl)-2-(4-bromophenyl)ethanone	1600514-91-7	C16H14Br2O3	414.093
  ——	2-allyl-4-bromo-1,3-dimethoxybenzene	1269809-26-8	C11H13BrO2	257.127
  ——	3-bromo-2,6-dimethoxystilbene	——	C16H15BrO2	319.198
  ——	(S)-5-<(3-bromo-2,6-dimethoxybenzamido)methyl>-2-pyrrolidone	145351-57-1	C14H17BrN2O4	357.204

反应信息

• 作为反应物：
  描述：

  3-溴-2,6-二甲氧基苯甲酸 在 sodium hydroxide 、 氯化亚砜 作用下， 以 氯仿 为溶剂， 反应 0.67h， 生成 瑞莫必利
  参考文献：
  名称：

  Potential neuroleptic agents. 2,6-Dialkoxybenzamide derivatives with potent dopamine receptor blocking activities

  摘要：

  A series of some novel N-(l-ethyl-2-pyrrolidinylmethyl)benzamides was synthesized and tested for dopamine receptor blockade in vivo by the ability to block the apomorphine syndrome in the rat. Several compounds were considerably more potent than sulpiride as dopamine receptor blockers and displayed low liability to induce extrapyramidal side effects (catalepsy) in the rat. The blockade of dopamine receptor activity in vivo was mainly confined to the levorotatory isomers having the S absolute configuration. The structure-activity relationships are discussed.

  DOI：

  10.1021/jm00353a003
• 作为产物：
  描述：

  2,6-二甲氧基苯甲酸 在 溴 作用下， 以 氯仿 为溶剂， 反应 1.5h， 以80%的产率得到3-溴-2,6-二甲氧基苯甲酸
  参考文献：
  名称：

  大叶紫苏（Coussarea macrophylla）的新蒽衍生物。

  摘要：

  五种新的天然蒽衍生物，1,4,10-三甲氧基蒽-2-甲醛（1），（1,4,10-三甲氧基-2-蒽-2-基）甲醇（2），1,4,8，从Cou菜中分离出10-四甲氧基蒽-2-甲醛（3），1,4,10-三甲氧基蒽-2-羧酸（4）和1,3-二甲氧基-2-甲氧基甲基蒽醌（5）以及三种已知的化合物，3-羟基-1-甲氧基-2-甲氧基甲基蒽醌（6），大麦草皮苷和3-表-大果酸。1-5的结构是在其光谱数据分析的基础上并通过全合成确定的。

  DOI：

  10.1021/np030066i

文献信息

• An improved palladium(II)-catalyzed method for the synthesis of aryl ketones from aryl carboxylic acids and organonitriles
  作者：Linda Axelsson、Jean-Baptiste Veron、Jonas Sävmarker、Jonas Lindh、Luke R. Odell、Mats Larhed

  DOI：10.1016/j.tetlet.2014.02.109

  日期：2014.4

  palladium(II)-catalyzed decarboxylative protocol for the synthesis of aryl ketones has been developed. The addition of TFA was shown to improve the reaction yield and employing THF as solvent enabled the use of solid nitriles and in only a small excess. Using this method, five different benzoic acids reacted with a wide range of nitriles to produce 29 diverse (hetero)aryl ketone derivatives in up to 94% yield.

  已经开发了钯（II）催化的用于合成芳基酮的脱羧方案。显示出添加TFA可提高反应产率，并且使用THF作为溶剂使得能够使用固体腈并且仅少量使用。使用这种方法，五种不同的苯甲酸与各种腈反应，可生成29种多样的（杂）芳基酮衍生物，收率高达94％。
• Structure−Activity Relationships of a Series of Substituted Benzamides:  Potent D₂/5-HT₂ Antagonists and 5-HT_1a Agonists as Neuroleptic Agents
  作者：Mark H. Norman、Greg C. Rigdon、William R. Hall、Frank Navas

  DOI：10.1021/jm950551d

  日期：1996.1.1

  A series of substituted (4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)benzamide derivatives was prepared and evaluated as potential atypical antipsychotic agents. The target compounds were readily prepared from their benzoyl chloride, benzoic acid, or isatoic anhydride precursors, and they were evaluated in vitro for their ability to bind to dopamine D2, serotonin 5-HT2, and serotonin 5-HT1a

  制备了一系列取代的（4-（4-（1,2-苯并噻唑-3-基）-1-哌嗪基）丁基）苯甲酰胺衍生物，并将其评估为潜在的非典型抗精神病药。目标化合物可以很容易地从其苯甲酰氯，苯甲酸或等位酸酐的前体制备，并在体外评估它们与多巴胺D2、5-羟色胺5-HT2和5-羟色胺5-HT1a受体结合的能力。为了评估这些化合物的潜在抗精神病活性，我们研究了它们在小鼠中抑制阿扑吗啡诱导的爬升反应的能力。进一步评估了选定的化合物，以确定其潜在的副作用。本文讨论了单取代的和多取代的苯甲酰胺的结构-活性关系。尽管几种类似物在体外和体内具有潜在的非典型抗精神病药活性，但蒽环酰胺77（1192U90）的药理作用却十分出色。这项研究的结果是，选择1192U90（2-氨基-N-（4-（4-（1,2-苯并噻唑-3-基）-1-哌嗪基）丁基）苯甲酰胺盐酸盐进行进一步评估。目前正在I期临床试验中，作为一种潜在的非典型抗精神病药。
• Palladium(II)-Catalyzed Decarboxylative Heck Arylations of Acyclic Electron-Rich Olefins with Internal Selectivity
  作者：Ashkan Fardost、Jonas Lindh、Per J. R. Sjöberg、Mats Larhed

  DOI：10.1002/adsc.201301004

  日期：2014.3.10

  electron‐rich olefins are still lacking. We herein report on palladium(II)‐catalyzed decarboxylative Heck arylations of linear electron‐rich olefins with excellent selectivity for the internal position. The method allows a variety of electron‐rich linear olefins to undergo arylation with ortho‐functionalized aromatic carboxylic acids, including heterocycles. The reaction mechanism has been explored with ESI‐MS

  尽管最近出现了脱羧CC键形成反应，但仍缺乏提供内部芳基化电子富集烯烃的方法。我们在此报告了线性（P2）催化的线性富电子烯烃的脱羧化Heck芳基化，其内部位置具有出色的选择性。该方法可使各种富电子的直链烯烃与包括杂环在内的邻官能化芳族羧酸进行芳基化。已通过ESI-MS研究探索了反应机理，以确认先前的发现，并揭示由于Heck产物与催化剂反应而形成的高度稳定的钯络合物。
• Piperazine derivatives useful as CCR5 antagonists
  申请人：Schering Corporation

  公开号：US06391865B1

  公开（公告）日：2002-05-21

  The use of CCR5 antagonists of the formula or a pharmaceutically acceptable salt thereof, wherein R is optionally substituted phenyl, pyridyl, thiophenyl or naphthyl; R1 is hydrogen or alkyl; R2 is substituted phenyl, substituted heteroaryl, naphthyl, fluorenyl, diphenylmethyl or optionally substituted phenyl- or heteroaryl-alkyl; R3 is hydrogen, alkyl, alkoxyalkyl, cycloalkyl, cycloalkylalkyl, or optionally substituted phenyl, phenylalkyl, naphthyl, naphthylalkyl, heteroaryl or heteroarylalkyl; R4, R5 and R7 are hydrogen or alkyl; R6 is hydrogen, alkyl or alkenyl; for the treatment of HIV, solid organ transplant rejection, graft v. host disease, arthritis, rheumatoid arthritis, inflammatory bowel disease, atopic dermatitis, psoriasis, asthma, allergies or multiple sclerosis is disclosed, as well as novel compounds, pharmaceutical compositions comprising them, and the combination of CCR5 antagonists of the invention in combination with antiviral agents useful in the treatment of HIV or agents useful in the treatment of inflammatory diseases.

  公开了使用CCR5拮抗剂的公式，其中 R是可选择的取代苯基，吡啶基，噻吩基或萘基; R1是氢或烷基; R2是取代苯基，取代杂环基，萘基，芴基，二苯甲基或可选择的取代苯基或杂环基烷基; R3是氢，烷基，烷氧基烷基，环烷基，环烷基烷基，或可选择的取代苯基，苯基烷基，萘基，萘基烷基，杂环基或杂环基烷基; R4，R5和R7是氢或烷基; R6是氢，烷基或烯基; 用于治疗HIV，固体器官移植排斥，移植物宿主病，关节炎，类风湿关节炎，炎症性肠病，特应性皮炎，牛皮癣，哮喘，过敏或多发性硬化症的方法，以及包含它们的新化合物，包含它们的药物组合物，以及CCR5拮抗剂与抗HIV治疗中有用的抗病毒剂或与治疗炎症性疾病中有用的药物的组合。
• Palladium-catalyzed highly regioselective and stereoselective decarboxylative arylation of unactivated olefins with aryl carboxylic acids
  作者：Xubo Qin、Changjun Chen、Lingjuan Zhang、Jianbin Xu、Yixiao Pan、Haoqiang Zhao、Jiahong Han、Huanrong Li、Lijin Xu

  DOI：10.1016/j.tet.2017.03.007

  日期：2017.4

  Palladium(II)-catalyzed highly regioselective and stereoselective decarboxylative arylation of unactivated olefins with aryl carboxylic acids has been developed. This method is applicable to a variety of unactivated olefins, including allylamides, long chain functionalized olefins and purely aliphatic olefins, leads to the formation of linear E-configured products in high yields. Both electron-rich

  已经开发了钯（II）催化的未活化烯烃与芳基羧酸的高度区域选择性和立体选择性脱羧芳基化。该方法适用于各种未活化的烯烃，包括烯丙基酰胺，长链官能化的烯烃和纯脂肪族的烯烃，导致形成线性E配置的产品，高产量。富电子和缺电子的芳基羧酸都是合适的芳基化试剂。发现溶剂，催化剂前体和氧化剂的选择对反应效率有重要影响。作为助溶剂和配体，DMSO对于催化至关重要。该化学方法扩大了烯烃与芳基羧酸的脱羧芳基化的范围，并提供了快速获得有用的未活化烯烃的线性芳基化产物的途径。